Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362735 | 0.81 | CHRNA4 (0.39) | CHRNA4RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL17611640 | 0.76 | PSMB8 (0.30) | CHRNA4PSMB8 | |
| SCHEMBL17611638 | 0.76 | PSMB8 (0.30) | CHRNA4PSMB8 | |
| SCHEMBL11722748 | 0.75 | CHRNA4 (0.36) | CHRNA4RAB9AALDH1A1L3MBTL1RAPGEF3 | |
| SCHEMBL26269687 | 0.74 | PSMB8 (0.39) | MLYCDCHRNA4PSMB8RAB9AMEN1 | |
| SCHEMBL7261615 | 0.73 | PSMB8 (0.36) | CHRNA4PSMB8RAB9AACACB | |
| SCHEMBL2122427 | 0.73 | — | — | |
| SCHEMBL28399251 | 0.73 | ALDH1A1 (0.50) | MLYCDRAB9ATDP1ALDH1A1L3MBTL1 | |
| SCHEMBL19456683 | 0.72 | RECQL (0.36) | CHRNA4PSMB8RAB9AMEN1KMT2A | |
| SCHEMBL8374791 | 0.72 | KDM4E (0.45) | MLYCDCLK1DYRK1ADYRK1BTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-12365674-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4570797-A2 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | AC IMMUNE SA (CH) | 2025-04-03 | — | — | US | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-1414802-B1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1263711-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414802-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| WO-2003011830-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| EP-1263711-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062704-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | MLYCD 607/4885CHRNA4 1900/4885CLK1 3805/4885 |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC10 | MLYCD 4011/4885CHRNA4 4013/4885CLK1 4539/4885 |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | MLYCD 607/4885CHRNA4 1900/4885CLK1 3805/4885 |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | MLYCD 1621/4885CHRNA4 1547/4885CLK1 3029/4885 |
| US-12365674-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC3 | MLYCD 4125/4885CHRNA4 3226/4885CLK1 4195/4885 |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | MLYCD 1240/4885CHRNA4 2571/4885CLK1 2798/4885 |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS1, NOS2 | MLYCD 4272/4885CHRNA4 1294/4885CLK1 965/4885 |
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | NLRP3, NLRP1, NOD1 | MLYCD 639/4885CHRNA4 4247/4885CLK1 3230/4885 |
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1B1, GUCY1B2, GUCY1A2 | MLYCD 1033/4885CHRNA4 2129/4885CLK1 2771/4885 |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | MLYCD 2885/4885CHRNA4 1794/4885CLK1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.